Evidence-Based and Emerging Diet Recommendations for Small Bowel Disorders.

"CONFLICTS OF INTEREST Guarantor of article: David Surendran Sanders, MBChB, MRCP, MD, FACG, FRCP. Specific author contributions: A.R., M.D.E.P., N.J.T., A.S., G.H., and D.S.S. drafted the initial manuscript. All authors reviewed and approved the final manuscript. Financial support: G.H. and A.S.: National Health and Medical Research Council (APP1084544), Centre for Research Excellence (APP170993). D.S.S. and A.R.: None declared. N.J.T. and M.D.E.P.: National Health and Medical Research Council grants. Potential competing interests: G.H. reports to be on the advisory boards Australian Biotherapeutics, Glutagen, and Bayer and received research support from Bayer, Abbott, Pfizer, Janssen, Takeda, and Allergan. He serves on the Boards of the West Moreton Hospital and Health Service, Queensland, UQ Healthcare, Brisbane, and the Gastro-Liga, Germany. He has a patent for the Brisbane aseptic biopsy device and serves as an editor of the Gastro-Liga Newsletter. D.S.S. receives an educational grant from Schaer (a gluten‐free food manufacturer). Dr. Schaer did not have any input in drafting of this manuscript. NJT reports nonfinancial support from HVN National Science Challenge NZ, personal fees from Aviro Health (Digestive health) (2019), Anatara Life Sciences, Brisbane (2019), Allakos (gastric eosinophilic disease) (2021), Bayer [IBS] (2020), Danone (Probiotic) (2018), Planet Innovation (Gas capsule IBS) (2020), Takeda, Japan (gastroparesis) (2019), twoXAR (2019) (IBS drugs), Viscera Labs (USA 2021) (IBS-diarrhea), Dr. Falk Pharma (2020) (EoE), Censa, Wellesley MA USA (2019) (Diabetic gastroparesis), Cadila PharmIncaceuticals (CME) (2019), Progenity Inc. San Diego (USA 2019) (Intestinal capsule), Sanofi-aventis, Sydney (2019) (Probiotic), Glutagen (2020) (Celiac disease), ARENA Pharmaceuticals (2019) (Abdominal pain), IsoThrive (2021) (esophageal microbiome), BluMaiden (2021), Rose Pharma (2021), Intrinsic Medicine (2021), and Comvita Mānuka Honey (2021) outside the submitted work; In addition, N.J.T. has a patent Nepean Dyspepsia Index (NDI) 1998, Biomarkers of IBS licensed, a patent Licensing Questionnaires Talley Bowel Disease Questionnaire licensed to Mayo/Talley, a patent Nestec European Patent licensed, and a patent Singapore Provisional Patent “Microbiota Modulation Of BDNF Tissue Repair Pathway” issued, “Diagnostic marker for functional gastrointestinal disorders” Australian Provisional Patent Application 2021901692. Committees: OzSage, Australian Medical Council (AMC) (Council Member); Australian Telehealth Integration Programme; MBS Review Taskforce; NHMRC Principal Committee (Research Committee) Asia Pacific Association of Medical Journal Editors. Boards: GESA Board Member, Sax Institute, Committees of the Presidents of Medical Colleges. Community group: Advisory Board, IFFGD (International Foundation for Functional GI Disorders), AusEE. Miscellaneous: Avant Foundation (judging of research grants). Editorial: Medical Journal of Australia (Editor in Chief), Up to Date (Section Editor), and Precision and Future Medicine, Sungkyunkwan University School of Medicine, South Korea, Med (Journal of Cell Press). N.J.T. is supported by funding from the National Health and Medical Research Council (NHMRC) to the Centre for Research Excellence in Digestive Health, and he holds an NHMRC Investigator grant. A.R., A.S., and M.D.E.P. declare no conflicts of interest."

"Financial support: G.H. and A.S.: National Health and Medical Research Council (APP1084544), Centre for Research Excellence (APP170993). D.S.S. and A.R.: None declared. N.J.T. and M.D.E.P.: National Health and Medical Research Council grants."